Roquefort to stretch itself with Oncogeni buy

22 June 2022

UK-based biotech Roquefort Therapeutics (LSE: ROQ) is to acquire Oncogeni in an all-share transaction which sources value at around £4 million ($4.9 million).

Privately-held Oncogeni is also a UK biotech company. It was founded by Nobel Laureate, Sir Martin Evans in 2019, with an experienced leadership team that is developing cell- and RNA-based cancer medicines, which Roquefort’s board believes is very complementary to its own existing pre-clinical drug development business.

"A transformational, value enhancing transaction for shareholders"Oncogeni has developed two families of innovative cell and RNA oncology medicines, both in pre-clinical development, which are protected by nine patents. The firm’s chief executive is Ajan Reginald, an experienced biotech boss who will take on the top job at the enlarged company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK